| # | Filing Date | Period End Date | Type | Report Link | 
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating | 
|---|
																	Avid Bioservices (NASDAQ:CDMO) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(...
																	RBC Capital analyst Sean Dodge downgrades Avid Bioservices (NASDAQ:CDMO) from Outperform to Sector Perform and raises the pr...
																	William Blair analyst Max Smock reiterates Avid Bioservices (NASDAQ:CDMO) with a Market Perform.
																	
																	
																	The per share purchase price represents a 13.8% premium to Avid's closing share price of $10.98 on November 6, 2024, the la...